Recently, there have been increasingly frequent reports on the occurrence of macrophage activation syndrome (MAS) in patients with inflammatory bowel disease (IBD). Clinically, MAS is characterized mainly by fever, hepatosplenomegaly, cytopenia, and elevated circulating ferritin and CD25. Mortality, even if diagnosed rapidly, is high.
SUMMARY Background
Recently, there have been increasingly frequent reports on the occurrence of macrophage activation syndrome (MAS) in patients with inflammatory bowel disease (IBD). Clinically, MAS is characterized mainly by fever, hepatosplenomegaly, cytopenia, and elevated circulating ferritin and CD25. Mortality, even if diagnosed rapidly, is high.
Aim
To identify all reports on MAS in IBD and to establish data on triggering agents, immunosuppression leading to MAS, and mortality.
Methods
A language unrestricted search on Pubmed and Scopus relating to the past 30 years was carried out by matching the following search-terms: h(a)emophagocytic lymphohistiocytosis OR h(a)emophagocytic lymphohistiocytic syndrome OR macrophage activation syndrome OR opportunistic infections OR cytomegalovirus OR Epstein-Barr virus AND Crohn's disease OR ulcerative colitis OR inflammatory bowel disease(s).
Results
Fifty cases were identified with an overall mortality of 30%. Virus-related MAS associated with cytomegalovirus or Epstein-Barr virus infections represents the main type of MAS, but in isolated cases bacterial infections precipitated the syndrome. In four cases (8%), a lymphoma was present at the time of MAS diagnosis or developed shortly thereafter. Thiopurine monotherapy was given before MAS onset in 56% of the patients, whereas multiple immunosuppression, including biologics, was administered to 24%.
Conclusions
In IBD patients, the syndrome appears to be triggered by infections, but genetic susceptibility may contribute to its development. Since immunosuppressive therapy represents the backbone of therapeutic interventions in IBD, with the risk of new, or the reactivation of latent infections, even more frequent cases of macrophage activation syndrome may be expected.
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INTRODUCTION
Macrophage activation syndrome (MAS) or Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening clinical syndrome characterised by high grade non-remitting fever, cytopenias affecting at least two of three lineages in peripheral blood, and hepatosplenomegaly associated with biochemical abnormalities, such as high circulating levels of serum ferritin, soluble interleukin-2 receptor (sCD25), and triglycerides, together with a decrease of circulating NK activity. Liver involvement is more frequent in pediatric cases but may be present in adults with variable levels of transaminases up to signs of acute liver failure and coagulopathy. Respiratory distress is frequently present and respiratory insufficiency represents a negative prognostic sign and may need assisted ventilation. The key feature of MAS is the presence of hemophagocytic CD163 + ve macrophages (HPC) in bone marrow ( Figure 1 ) or lymph-node aspirates.
Diagnosis is based on the fulfillment of a series of criteria established in 2004 1 (Table 1) for HLH associated with autosomal recessive disorders (familial HLH, fHLH) that lead to defects involving perforin, 2 
a molecule implicated in apoptosis induction of virus-infected cells or tumor cells by cytolytic immune cells such as natural killer (NK) cells or cytotoxic T lymphocytes (CTL).
Other mutations have been identified on the UNC13D gene, that encodes for Munc13-4, a protein involved in perforin delivery to target cells, 3 and the genes of synthaxin 11 or Munc18-2, both proteins which regulate and control membrane fusion. 4 Other genetically determined Macrophage activation syndrome (MAS) complicating inflammatory bowel diseases (IBD) has received little attention in literature, but the increasing frequency of reported cases led us to systematically review this issue in order to identify precipitating factors such as immunosuppressive therapy, infectious agents, and outcome. We use the term MAS in order to keep it distinct from familial HLH.
METHODS
A computerized search without language restriction was conducted on literature of the past 30 years (PubMed, Scopus, and within reviews). Due to the variety of names used for the syndrome, a combination of terms was used: h(a)emophagocytic lymphohistiocytosis OR h(a)emophagocytic lymphohistiocytic syndrome OR macrophage activation syndrome OR opportunistic infections OR cytomegalovirus OR Epstein-Barr virus AND Crohn's disease OR ulcerative colitis OR inflammatory bowel disease(s). A report was considered eligible for inclusion when data on gender, age, IBD-type, treatment before MAS onset, triggering agent, and outcome were stated. Reports were excluded when more than two of the requested items were not reported. Furthermore, additional data on the methodology employed to identify the triggering agents and therapy of MAS were collected. Case finding strategy is represented in Figure 2 .
RESULTS
We identified 50 cases of MAS associated with IBD including two unpublished cases from our clinic and one case from the IBD-centre of Palermo (Table 2) , . The first report was published in 1988 followed by six isolated reports over the following 16 years, up to 2004. Thereafter, we observed a sharp increase in published cases with an additional 41 cases between 2005 and October 2012, 22 of them in the previous 24 months.
We excluded three cases from analysis: one case from a series with different background pathologies because of insufficient clinical data, 52 and two cases of EBV infection (one of them fatal) and clinical features which resembled MAS, but diagnosis of MAS was not made by the authors.
53, 54
Case description of yet unpublished cases Clinic of Messina: Case 1: a 38 year-old woman was admitted to our hospital because of high grade fever unresponsive to antibiotics, lasting 5 days. She had been diagnosed with ulcerative colitis 8 years before and was in stable remission while on azathioprine at a dose of 2 mg/kg/day over the past 8 years. On admission, pancytopenia (leucocytes 1800/μl, hemoglobin 92 g/L, platelets 85 000/μl) and mild transaminitis were present. An ultrasound evaluation of the abdomen revealed an enlarged spleen and a moderate hepatomegaly; no lymph nodes were identified. A chest film was negative. Azathioprine was stopped and repeated blood cultures and search for EBV, CMV, human Herpes Virus-6 (HHV-6), and serology for leishmania yielded negative results. She was treated empirically with broad-spectrum antibiotics, methylprednisolone, and filgrastim. High serum ferritin and triglycerides, hyponatremia, and absent activity of NK cells were suggestive for MAS, but a bone marrow aspirate was negative for hemophagocytosis. Her clinical picture evolved rapidly, and death due to multiorgan failure occurred 10 days after admission. Clinical diagnosis, based on clinical and blood parameters was consistent with MAS. Authorization for a post-mortem investigation was denied. Case 2: a 72-year-old woman was diagnosed with Crohn's ileitis which responded well to oral mesalazine and systemic steroids. She developed steroid-dependency in a few months and azathioprine was added 1 year after diagnosis at 2.2 mg/kg/day in order to control symptoms. Six months later she was admitted to our hospital because of high grade fever, unresponsive to antibiotic therapy and azathioprine withdrawal. On admission, she presented acutely ill, dyspneic (oxygen saturation at room air 85%), malnourished (albumin, 22 g/L), with leucopenia (2200/mL) and anemia (hemoglobin 88 g/L). On physical examination, herpetic lesions were noted at her lips and i.v. treatment with acyclovir together with methylprednisolone and parenteral nutrition was started. An ultrasound examination of the abdomen revealed a slightly enlarged spleen and a homogeneous, hypoechoic wall thickening (12 mm) of the ileum proximally to the known Crohn's localization, raising the suspect of a small bowel lymphoma. A chest film was positive for significant pleural effusion, which was repeatedly drained in order to improve ventilation. The search for serum CMV-DNA yielded positive results and i.v. ganciclovir was commenced. High serum ferritin, together with hypertriglyceridemia and absent NK activity led to the diagnosis of CMV-related MAS. After improvement of the clinical picture and blood parameters, she was transferred to our Surgery Unit and underwent resection of the distal 50 cm of the ileum. Histopathological evaluation of the resected bowel was consistent with intestinal B-cell lymphoma and Crohn's disease. After discharge, the patient was followed by hematologists, but died 3 months later, after a second chemotherapy cycle.
Clinic of Palermo: a 54-year-old man, diagnosed with Crohn's disease of the ileum in 2007 by means of colonoscopy, histology, and magnetic resonance imaging, was initially treated with steroids due to fever and mild diarrhea. The patient initially responded with clinical remission, but relapsed early with high-grade fever. A complete screening for infection was negative, so steroids were re-started with an initial response, followed again by early relapse with fever and arthralgias. Azathioprine was added and the patient went into remission for 2 years, but in December 2009 he relapsed with high fever unresponsive to steroids. Infliximab was initiated followed by complete remission until October 2011 when he relapsed again with high fever and arthralgias. At admission, splenomegaly and an increase in size of abdominal lymph-nodes were observed; a complete screening of infectious diseases through blood and urine cultures for bacterial, viral and fungal infections was performed. HSV-1, with typical labial lesions, was present and i.v. acyclovir was started. Despite negative bacterial cultures, an empiric broad-spectrum antibiotic treatment was started. At this moment, red blood cell, platelet and leucocyte counts were normal and a bone marrow aspirate was negative. Subsequently, red blood cell, platelet and leucocyte counts decreased gradually and serum ferritin increased to more than 10000 g/dL while serum triglycerides rose to 800 mg/dL. Bone marrow aspirate was repeated and haemophagocytosis was identified (Figure 1) . A treatment regimen according to the treatment protocol HLH-04 was established with dexamethasone, etoposide and cyclosporine A, but the patient's conditions deteriorated and he died 10 days later. In the retrieved cases, gender distribution was equal (21 females, 24 males, five not reported) in the whole series and 36/50 (72%) were adults, aged from 19 to 72 years; the median age in adults was 28.5 years. The underlying bowel diseases in adults were Crohn's disease (CD) in 26/36 (72%), and ulcerative colitis (UC) in 10 patients (28%). In the 14 pediatric patients, 13 (92.8%) were diagnosed with CD and one with inflammatory bowel disease unclassified (IBDU) (6%).
Overall mortality was 30%. In adults, death occurred in 10/36 (28%), whereas fatal outcome was observed in 5/14 pediatric patients (38%). Where indicated, the final cause of death was multiorgan failure in six patients; hepatic failure, respiratory failure, gastrointestinal bleeding, or intracerebral hemorrhage were reported in other patients. One patient died during emergency surgery due to a perforated gastric ulcer. Two adult patients with lymphoma died during the follow-up after MAS had been successfully treated (our clinic, 41 ).
Treatment before MAS onset. Treatment with thiopurines was reported in 39/50 patients with a duration that ranged from 4 months to 8 years. Thiopurine monotherapy was administered in 28/37 patients, whereas in the remaining cases thiopurines were associated with steroids (three cases), with infliximab (seven patients) or both (one case). In two patients, an immunosuppressor without indication of the exact molecule was associated with infliximab and steroids 25 or was used as single therapeutic agent, 30 respectively. Infliximab was used as single therapy in three patients, associated with steroids in 1 patient. All other patients were treated with a combination with thiopurines. Duration of infliximab treatment, when reported, ranged from 0.5-60 months. In pediatric patients, thiopurines were administered to 13/14 patients, as monotherapy in 10/13, or combined with steroids (one patient) or with infliximab (two patients). In one patient treatment was not indicated. When indicated, thiopurine dosing ranged from 0.9 to 3.15 mg/kg/day for azathioprine and 1.4 to 1.76 mg/kg/ day for mercaptopurine. In six patients (Table 3) , determination of erythrocyte concentrations of 6-thioguanine nucleotides (6-TGN), and in four patients also those of 6-methylmercaptopurines (6-MMP), was available shortly before onset of MAS, showing the former levels to be within the therapeutic range and the latter below the toxic limit. 27, 44, 50, 51 Mesalazine or sulphasalazine alone were reported in one patient, steroids alone in two patients and steroids followed by colectomy in one patient with UC.
Triggers associated with MAS onset. Viral infections were causally associated in 39/50 patients (78%) with infections due to EBV equally frequent to those due to CMV (19 EBV, 20 CMV); one CMV/herpes simplex virus (HSV) co-infection was seen (own observation). Interestingly, in pediatric patients, EBV was identified in 11/14 (79%), CMV or Acinetobacter in one case each, and in one patient no infectious agent was indicated.
Primary EBV infections were reported in 12 patients, while the remaining were consistent with EBV reactivation. Primary CMV infections were diagnosed in 7 out of 20 patients.
In the whole series, bacterial or fungal infections were identified in five cases. Among these latter agents Mycobacterium tuberculosis was reported in three patients and all these patients received infliximab.
In seven cases, no infectious agent was identified. Three cases were associated with lymphomas; one hepatosplenic T-cell lymphoma (HSTCL) in a 21-year old male treated with infliximab + MP, 41 one B-cell lymphoma in a 72-year old woman treated with AZA for CD (own observation), and one NK/T-cell lymphoma in an 11-year old boy treated with infliximab + AZA for IBDU 36 : the two former patients died due to neoplastic disease, the latter patient died due to MAS.
Clinical presentation of MAS in IBD
With respect to the diagnostic criteria of HLH (Table 1) , and given that not all reports indicate numeric data, clinical features included temperature ranging from 38.6 to 40°C in 92% of all cases. In four reports, no detailed data were available. Enlargement of liver and spleen was reported in almost half of patients. In all cases, leucopenia was reported with a median value of 1200/mL (range 300-3100/mL). In roughly 30% cases, leucocytes were above the limit set by Henter et al. 1 Median haemoglobin levels were 87 g/L (range 65-133 g/L), with only 8% above the upper limit. Median platelet counts were 80 000/mL (range 8000-187 000/mL) with 10% above the limit indicated by diagnostic criteria. Serum ferritin was the most frequently reported variable, with all of the reported values above the threshold of 500 μg/ L (median value 5000 μg/L; range 583-52 397 μg/L), whereas triglycerides were normal in 16% with a median concentration of 339 mg/dL (range 162-1235 mg/dL). Only seven reports included serum fibrinogen with a range from 0.3 to 1.7 g/L (normal in 1/7) and another seven gave circulating levels of CD25 (range 5941-39 222 U/mL). NK activity was reported in only four reports with values compatible with HLH.
Treatment of established MAS. Besides withdrawal of immunosuppressive therapy, sufficient to resolve the clinical picture in one patient, 20 and specific treatment for recognized bacterial, fungal or viral infections, various approaches were described including administration of i.v. immunoglobulins, plasmapheresis, granulocyte-colony stimulating factor, and foscarnet in addition to ganciclovir. Vincristine and/or cyclophosphamide were used in EBV-related lymphoproliferative disorders. The full HLH-04 protocol, published in 2007, 1 an association of dexamethasone, etoposide, and cyclosporine A, was employed in 13 patients, starting from 2009 (eight patients with EBV, three with CMV, and two patients without identification of an infectious agent). Death occurred in four of them. Four patients with EBV-related MAS were treated successfully with one or more administrations of rituximab, an anti-CD20 antibody, whereas one patient died despite this treatment. Interestingly, infliximab was administered successfully in a pediatric MAS virus-negative patient formerly treated with mercaptopurine. 44 Outcome after MAS. Follow-up ranging from 6 months to 3 years was reported in 20 of the surviving patients. Apparently, no patient resumed the same immunosuppressor given before MAS-onset. Four patients remained in remission on oral and topical mesalazine, 20, 41, 45, 46 in two patients methotrexate was started successfully, one patient is on low-dose prednisolone (10 mg/day) and one is on low dose cyclosporine (target serum trough level 100 ng/mL, personal communication from ref 51) treatment. Finally, one patient is on an empirical anti-MAP (Mycobacterium avium spp. paratuberculosis) therapy 45 and one patient is on evaluation for stem cell transplantation. 48 
DISCUSSION
In the retrieved records, most of the patients suffered from CD and all except five patients were under immunosuppressive therapy. The prevalence of CD may reflect the more frequent use of immunomodulators in this disease compared to UC rather than a disease-related susceptibility to MAS. Roughly one out of three patients died. Although we have no epidemiologic data on the incidence of MAS in IBD, it is plausible that the rising frequency is due to an improved awareness on the part of gastroenterologists rather than to a phenomenon that has increased over the past 5 years. Immunomodulators such as AZA or MP have been constantly used over the past 30 years throughout the world, and biologic therapies have now been in use for almost 10 years. The main therapeutic intervention prior to onset of MAS was with thiopurines, while the duration of thiopurine treatment seems not to have been significant (range 4-69 months).
Other treatments for IBD include biologics, infliximab alone or in combination with steroids or thiopurines. Adalimumab has not yet been reported in IBD to be associated with MAS, but has been reported in one patient with rheumatoid arthritis. 55 Surprisingly, salazopyrin and mesalazine were reported in one patient each as the only therapy before MAS onset, pointing to genetic factors, thus making immunosuppression as the only causative factor unlikely. It is possible that the occurrence of MAS in patients with IBD is the result of a fatal combination between persistence of, or a new infection with, a virus, the effect of immunosuppressive therapy weakening immune surveillance, and the potential presence of a genetic susceptibility. Thioupurines inhibit the activity of CD4 Tlymphocytes by inducing apoptosis through inhibition of Rac1 56 thus weakening defence against viral infections.
Biologics, on the other hand, seem to expose patients more to fungal or bacterial agents. 57 In systemic lupus erythematosus (SLE) patients, a killing defect of NK cells has been demonstrated which is ultimately accentuated by a reduction of NK cells induced by azathioprine. 58 Likewise in kidney transplant patients 59 there is a significant difference in NK cell activity depending on the immunosuppressive drug used to prevent graft rejection. Indeed, the combination of tacrolimus/mycophenolate mofetil did significantly better in terms of less NK cell reduction and less NK cytotoxicity reduction than the combination with cyclosporine/azathioprine. In an experimental murine model of MAS, repeated stimulation of the toll-like receptor 9 (TLR9) with CpG DNA precipitates the syndrome. 60 EBV is known to trigger TLR9, and high loads of EBV were found in macrophages of patients with MAS. 33 In the juvenile form of SLE, where MAS appears to have a high clinical impact, 61 overstimulation of TLR9 is believed to be induced by autoantigens. 62 In sJIA-related MAS, occult MAS appears to be present in up to 30% 9, 63 and it has been hypothesized that an intrinsic hyperactivity of TLR/IL-1R signaling may trigger evolution to MAS 64 . The common denominator is an inefficacious response to antigens that leads to an overwhelming Th1/Th1-related cytokine production and, finally, to macrophage activation in the bone marrow, liver, and spleen leading to its principal feature i.e. a two-to three-line cytopenia. It is becoming apparent that compared to other immunomodulators or biologics, thiopurines carry a risk for reactivation of viral infections other than CMV, including activating warts (human papilloma virus, HPV) with possible cervical dysplasia/cancer, 65 and Ebstein-Barr virus (EBV) with an increased risk of related lymphomas. 66 Herpes viruses, after the primary infection, enter in latency in the human organism but remain under the control of the immune system, namely NK cells and cytotoxic T cells. Latent varicella-zoster virus (VZV) and HSV are harbored in neural cells, whereas latent EBV and CMV reside in precursors of myeloid derived monocytes and dendritic cells. 67 The figures for seroprevalence in healthy adults for CMV, EBV, HSV, and VZV reach 100%, 96%, >90%, and >90%, respectively [68] [69] [70] [71] [72] , which means that nearly every patient is at risk for reactivation. Interestingly, in the retrieved cases, Aliment Pharmacol Ther12 patients were reported to have a primary EBV infection and 7 patients were classified as primary CMV infection. Despite these findings, no recommendation concerning a search for antibodies against either EBV or CMV has been advised in the most recent ECCO guidelines on opportunistic infections. 73 Since TNF plays a role in the inhibition of viral replication, 74 much attention has been paid to potential viral infections in anti-TNF treated patients. In a large register from rheumatologic patients in Spain, VZV and HSV infections were the most frequent viral infections in patients treated with biologics, ranking however after bacterial or fungal complications. 75 Atypical varicella and VZV reactivation have been reported 76 and severe infections due to VZV are reported among the most frequent viral complications of anti-TNF therapy in the French RATIO registry, followed by HSV. However, the overall risk of reactivation of latent herpes viruses in patients on biologics appears to be low; at least after 3 months of therapy in IBD 77 and after 6 weeks in rheumatoid arthritis. 78 Concerning CMV, T-cell response to CMV was investigated in 25 patients on anti-TNF therapy, showing that the interferon-c response of CD4 + ve cells and the proliferative response were maintained upon CMV antigen stimulation 79 . Indeed, in most of the retrieved cases, and other reports on CMV infections 80 , patients were on concomitant thiopurine treatment. EBV is a virus with the potential of inducing malignant lymphomas, and many studies deal with this topic. 81 Investigating reactivation of EBV on anti-TNF therapy, however, yielded negative results in rheumatologic 78, 82 as well as in IBD patients. 77 Despite these considerations, in the past few years a growing number of reports have been published on IBD patients with opportunistic infections complicated by a syndrome of macrophage and T-cell activation, accompanied by a potentially fatal cytokine storm and overwhelming inflammatory reaction, the MAS syndrome, which, in the present review, reaches a mortality rate of 30%. For comparison, over the past 5 years, one of the major concerns regarding therapeutic interventions in IBD has been represented by HSTCL, a highly lethal lymphoma affecting mostly young males treated with thiopurine monotherapy or with combined therapies (thiopurines plus biologics). Altogether, 38 cases of HSTCL are reported, 23 of them on thiopurine monotherapy 83 with a range of therapy duration between three and 17 years. In the present series of MAS, a 21-year old male patient was diagnosed with HSTCL after MAS onset and died somewhat later due to sepsis. 40 It appears that one of the major problems is to recognize the syndrome, which may present with a variety of symptoms, ranging from neurologic-predominant signs to acute liver failure. In fact, two of the retrieved reports were excluded as MAS was not diagnosed despite a compatible clinical picture. 53, 54 Misinterpretation of clinical/ biochemical signs leads to diagnostic delays, since fever and cytopenia may represent side effects of thiopurine therapy, whereas cytopenia may be present in patients on biologics. The presence of hemophagocytic CD163 + ve macrophages in bone marrow or lymph-node aspirates, may be missed, at least in initial stages, and negative histology should not rule out MAS, 84 whereas repeated aspirates retard diagnosis. The clinical picture, together with the infiltration of bone marrow or liver by activated macrophages, may lead to the correct diagnosis. Additional features such as the reduction/absence of peripheral CD8 + ve NK cells, 85 are present in early stages in nearly all patients. 86 Other biochemical signs, e.g. a highly elevated serum ferritin, most likely expression of the acute phase response, are almost always present and an early decrease after therapy start may be used as prognostic marker for a more favourable outcome in HLH. 87 Other immunologic markers are raised in MAS, such as sCD25 and the receptor for haemoglobin/haptoglobin complexes CD163. CD25 is believed to have an immunosuppressive action as it binds circulating IL-2, but may reflect in MAS only the complete dysregulation of the immune system. 88 A proinflammatory action of CD25, by enhancing the IL-17 immune response, has been shown recently in an animal model of autoimmune disease. 89 CD163 is involved in clearance and endocytosis of haemoglobin/ haptoglobin complexes by macrophages and may protect tissues from free haemoglobin-mediated oxidative damage. In sJIA, high circulating levels of sCD25 and sCD163 are promising diagnostic markers for early diagnosis of MAS together with serum ferritin 90 and should be investigated in IBD patients with suspected MAS. With regard to therapy, treatment of the underlying infection is mandatory and may require empirical treatment in the first 24-48 h. If MAS is suspected, a broad search for infectious agents with appropriate techniques is necessary, including determination of EBV-, CMV-, human herpes virus-6 (HHV-6)-DNA, search for Mycobacterium tuberculosis, histoplasmosis (urines), repeated blood and urinary cultures, etc. In hyperacute situations, additional immunosuppression with steroids, cyclosporine A, or etoposide may be required (see Henter, ref 1) . Other treatment options, e.g. rituximab, immunoglobulins, or intrathecal dexamethasone are extensively reviewed in Jordan et al 91 .
In conclusion, in IBD patients, thiopurine treatment in particular is associated with MAS, most likely by promoting viral reactivation through inhibition of NK and cytotoxic T cells. However, although less frequent, almost every treatment and a variety of infectious agents may lead to this syndrome. Overall, mortality is high, especially in pediatric patients. It is possible that genetic susceptibility, together with reactivated latent or primary viral infections, contributes to the occurrence of MAS. Genetic determinants should be investigated in IBD patients with MAS. AUTHORSHIP Guarantor of the article: Walter Fries. Author contributions: WF and AC designed the research study, performed and analyzed the literature search, and drafted the paper. MC contributed the case from Palermo and critically reviewed the manuscript. All authors approved the final version of the manuscript.
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